Pierre Fabre, XtalPi Ink AI Drug Discovery Deal in Oncology
Castres – November 09, 2026 -- Laboratoires Pierre Fabre and XtalPi Holdings Limited (2228.HK) have signed a drug discovery agreement that includes an upfront payment, multiple milestone payments and downstream economic participation. Neither company disclosed the financial terms.
XtalPi to design small molecules de novo against undisclosed targets
XtalPi will apply its integrated AI capabilities and robotics platform to design and deliver novel small molecule therapeutics. The research programs cover oncology, potentially dermatology, and rare diseases. The targets were not named.
Pierre Fabre takes on compound selection and clinical and commercial development
Pierre Fabre will contribute expertise in disease biology, discovery, translational research and clinical development to select and advance the most promising compounds. It will also be responsible for subsequent clinical and commercial development.